Total Payments
$111,492
2024 Payments
$21,487
Companies
19
Transactions
103
Medicare Patients
341
Medicare Billing
$43,411
Payment Breakdown by Category
Other$62,829 (56.4%)
Research$34,225 (30.7%)
Consulting$9,810 (8.8%)
Travel$2,457 (2.2%)
Food & Beverage$1,926 (1.7%)
Education$245.23 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,803 | 17 | 53.6% |
| Unspecified | $34,225 | 14 | 30.7% |
| Consulting Fee | $9,810 | 4 | 8.8% |
| Travel and Lodging | $2,457 | 8 | 2.2% |
| Food and Beverage | $1,926 | 41 | 1.7% |
| Honoraria | $1,912 | 2 | 1.7% |
| Long term medical supply or device loan | $1,115 | 12 | 1.0% |
| Education | $245.23 | 5 | 0.2% |
Payments by Type
General
$77,267
89 transactions
Research
$34,225
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $54,965 | 35 | $0 (2024) |
| Ichnos Sciences Inc. | $34,225 | 14 | $0 (2020) |
| Stemline Therapeutics Inc. | $12,209 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $5,740 | 6 | $0 (2020) |
| PFIZER INC. | $1,914 | 3 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,146 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $685.00 | 1 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $253.26 | 4 | $0 (2017) |
| Astellas Pharma US Inc | $99.95 | 1 | $0 (2017) |
| Amgen Inc. | $51.90 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,487 | 26 | Gilead Sciences, Inc. ($15,167) |
| 2023 | $18,874 | 14 | Gilead Sciences, Inc. ($11,165) |
| 2022 | $28,621 | 18 | Gilead Sciences, Inc. ($28,621) |
| 2021 | $1,902 | 2 | PFIZER INC. ($1,890) |
| 2020 | $39,965 | 20 | Ichnos Sciences Inc. ($34,225) |
| 2019 | $39.61 | 3 | Lilly USA, LLC ($17.49) |
| 2018 | $12.57 | 1 | PFIZER INC. ($12.57) |
| 2017 | $590.14 | 19 | Millennium Pharmaceuticals, Inc. ($253.26) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $599.57 | General |
| Category: ONC | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $96.66 | General |
| Category: ONC | ||||||
| 10/25/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $126.00 | General |
| Category: ONC | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,860.00 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/28/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,480.00 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: ONC | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $65.07 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 02/27/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 02/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 02/16/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $94.77 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Other Study Related Fees | Ichnos Sciences Inc. | $34,225 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 53 | 88 | $20,603 | $6,808 |
| 2022 | 4 | 74 | 144 | $33,658 | $11,517 |
| 2021 | 3 | 76 | 133 | $28,923 | $9,859 |
| 2020 | 4 | 138 | 226 | $71,074 | $15,227 |
Total Patients
341
Total Services
591
Medicare Billing
$43,411
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 77 | $17,402 | $5,679 | 32.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $3,201 | $1,129 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 103 | $23,278 | $7,761 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 17 | $5,151 | $1,854 | 36.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $3,201 | $1,225 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $2,028 | $676.92 | 33.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 34 | 84 | $18,984 | $6,489 | 34.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 17 | 17 | $4,947 | $1,799 | 36.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 25 | 32 | $4,992 | $1,571 | 31.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 145 | $44,626 | $9,110 | 20.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 25 | 25 | $10,055 | $2,886 | 28.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 19 | 22 | $9,165 | $1,853 | 20.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 28 | 34 | $7,228 | $1,377 | 19.1% |
About Dr. Hadeel Assad, MD
Dr. Hadeel Assad, MD is a Hematology & Oncology healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2011. The National Provider Identifier (NPI) number assigned to this provider is 1851684393.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hadeel Assad, MD has received a total of $111,492 in payments from pharmaceutical and medical device companies, with $21,487 received in 2024. These payments were reported across 103 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($59,803).
As a Medicare-enrolled provider, Assad has provided services to 341 Medicare beneficiaries, totaling 591 services with total Medicare billing of $43,411. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Detroit, MI
- Active Since 05/17/2011
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851684393
Products in Payments
- Trodelvy (Drug) $54,921
- ICHNOS ISB 1302-103 (Drug) $34,225
- Orserdu (Drug) $12,209
- IBRANCE (Drug) $1,890
- KISQALI (Drug) $1,135
- Enhertu (Drug) $805.20
- NINLARO (Drug) $142.02
- VELCADE (Drug) $111.24
- Cabometyx (Drug) $44.82
- Aranesp (Biological) $27.37
- Rubraca (Drug) $26.83
- Imbruvica (Drug) $24.11
- Pomalyst (Drug) $22.98
- VARUBI (Drug) $21.86
- Iclusig (Drug) $17.55
- VERZENIO (Drug) $17.49
- NovoSeven RT (Drug) $16.04
- Neulasta (Biological) $13.46
- MYLOTARG (Biological) $12.57
- TALZENNA (Drug) $11.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Detroit
Mohammed Al Hallak, M.d, M.D
Hematology & Oncology — Payments: $405,253
Hematology & Oncology $405,253
Wasif Saif, Md, MD
Hematology & Oncology — Payments: $134,504
Hematology & Oncology $134,504
Harsh Shah, Do, DO
Hematology & Oncology — Payments: $57,818
Hematology & Oncology $57,818
Dr. Susan Harold, Md, MD
Hematology & Oncology — Payments: $29,081
Hematology & Oncology $29,081
Muhammad Usman, M.d, M.D
Hematology & Oncology — Payments: $16,264
Hematology & Oncology $16,264
Andrew Kin, Md, MD
Hematology & Oncology — Payments: $13,374
Hematology & Oncology $13,374